Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr;35 Suppl 1(Suppl 1):25-27.
doi: 10.37201/req/s01.05.2022. Epub 2022 Apr 22.

Ceftobiprole medocaril

R Méndez  1 , A Latorre, P González-Jiménez
Affiliations
Review

Ceftobiprole medocaril

R Méndez et al. Rev Esp Quimioter. 2022 Apr.

Abstract

Ceftobiprole medocaril is a broad-spectrum 5th-generation cephalosporin with activity against Gram-positives such as methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae, and against Gram-negatives such as Pseudomonas aeruginosa. The recommended dose is 500 mg every 8 h in 2-hour infusions. Various clinical trials have demonstrated its usefulness in the treatment of community-acquired pneumonia and nosocomial pneumonia, with the exception of ventilator-associated pneumonia. In summary, it is a very useful antibiotic for the treatment of pneumonia.

PubMed Disclaimer

Conflict of interest statement

Authors declare no conflicts of interest

References

    1. Morosini MI, Díez-Aguilar M, Cantón R. Mechanisms of action and antimicrobial activity of ceftobiprole. Rev. Esp. Quimioter. 2019. - PMC - PubMed
    1. Pillar CM, Aranza MK, Shah D, Sahm DF. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent Gram-positive and Gram-negative isolates of European origin. J Antimicrob Chemother 2008. DOI:10.1093/jac/dkm492. - DOI - PubMed
    1. Lagacé-Wiens PRS, Rubinstein E. Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia. Expert Opin. Drug Metab. Toxicol. 2013. DOI:10.1517/17425255.2013.788150. - DOI - PubMed
    1. Lodise TP, Pypstra R, Kahn JB, et al. . Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrob Agents Chemother 2007. DOI:10.1128/AAC.01181-06. - DOI - PMC - PubMed
    1. Schmitt-Hoffmann A, Nyman L, Roos B, et al. . Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother 2004. DOI:10.1128/AAC.48.7.2576-2580.2004. - DOI - PMC - PubMed

MeSH terms